Original sentence: If mitemcinal can be shown to be as effective a prokinetic agent, it would represent an advance in the field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria.It is a subsidiary controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014.Mitemcinal was believed to have strong prokinetic properties, like its parent molecule, but lack antibiotic properties.Presently, erythromycin is commonly used off-label for gastric motility indications such as gastroparesis.Scientists at Chugai discovered an erythromycin-derived motilin agonist called mitemcinal (GM-611 or 3′-N-dimethyl-11-deoxy-3′-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin).is a drug manufacturer operating in Japan
Edited sentence: ) Mitemcinal was believed to have strong prokinetic properties, similar to its parent molecule, but lack antibiotic properties.If Mitemcinal can be shown to be as effective a prokinetic agent, it would represent a significant advance in the GI field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria.Presently, erythromycin is commonly used off-label for gastric motility indications such as Gastroparesis.Previous to Roche's takeover in 2002, Chugai was a pioneering discoverer of many important pharmaceutical compounds.Scientists at Chugai discovered an erythromycin-derived motilin agonist called Mitemcinal (aka GM-611 or 3'-N-dimethyl-11-deoxy-3'-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin.is a subsidiary drug manufacturer operating in Japan controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014